Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.43 USD | -2.02% | -12.27% | +25.26% |
May. 06 | Sector Update: Health Care Stocks Higher in Late Afternoon Trading | MT |
May. 06 | Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows | MT |
Chart calendar Lyell Immunopharma, Inc.
Upcoming events on Lyell Immunopharma, Inc.
Past events on Lyell Immunopharma, Inc.
2024-05-14 11:40 am | BofA Securities Health Care Conference |
2024-05-06 08:00 am | Q1 2024 Earnings Release |
2024-04-09 05:30 pm | American Association for Cancer Research Meeting - Abstract Number: 6593 |
2024-04-09 12:00 pm | American Association for Cancer Research Meeting - Abstract Number: 4067 |
2024-04-07 04:30 pm | American Association for Cancer Research Meeting - Abstract Number: 49 |
2024-03-26 03:30 pm | H.C. Wainwright Cell Therapy Virtual Conference |
2024-03-04 11:10 am | TD Cowen Health Care Conference |
2024-02-28 04:05 pm | Q4 2023 Earnings Release |
2024-01-10 11:15 am | JPMorgan Healthcare Conference |
2023-11-07 04:05 pm | Q3 2023 Earnings Release |
2023-11-04 02:55 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 754 |
2023-11-04 02:55 pm | Society for Immunotherapy of Cancer Meeting - Abstract No.: 278 |
2023-11-03 03:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract No.: 393 |
2023-11-03 03:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract No.: 1047 |
2023-11-03 03:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract No.: 747 |
2023-11-03 03:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 379 |
2023-09-27 03:35 pm | Cantor Global Healthcare Conference |
2023-09-12 09:00 am | H.C. Wainwright Global Investment Conference |
2023-09-11 04:55 pm | Morgan Stanley Global Healthcare Conference |
2023-08-08 04:05 pm | Q2 2023 Earnings Release |
Annual results
Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 10,7 9,69 9.92% | 84,7 43,7 93.91% | 0,13 0,12 5.48% | 0,00 |
EBITDA Million USD | Released Forecast Spread | 0,00 | -201 -228 11.72% | -169 -203 16.85% | -227 -220 -3.06% | -218 |
EBIT Million USD | Released Forecast Spread | 0,00 | -215 -237 9.52% | -187 -224 16.64% | -247 -250 1.11% | -229 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | -183 -242 24.28% | -235 -240 2.14% | -222 |
Net income Million USD | Released Forecast Spread | -204 | -250 -238 -5.01% | -183 -243 24.67% | -235 -240 2.14% | -222 |
EPS USD | Released Forecast Spread | 0,00 | -1,84 -1,43 -28.88% | -0,74 -0,98 24.59% | -0,93 -0,96 2.83% | -0,87 |
Announcement Date | 12/05/21 | 29/03/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,55 1,50 -63.13% | 35,7 1,60 2133.81% | 0,00 2,70 -99.89% | 48,4 2,80 1628.07% | 0,07 0,00 - | 0,03 0,00 - | 0,03 0,00 - | 0,01 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
EBITDA Million USD | Released Forecast Spread | -60,8 -61,4 0.93% | -53,9 -51,7 -4.31% | -54,5 -53,6 -1.57% | |||||||||||
EBIT Million USD | Released Forecast Spread | -68,6 -69,7 1.64% | -37,3 -69,7 46.5% | -66,4 -75,5 11.99% | -14,8 -76,7 80.72% | -62,6 -71,6 12.64% | -65,9 -72,0 8.51% | -59,0 -68,3 13.56% | -59,5 -62,7 5.12% | -55,6 -59,4 6.44% | -56,0 | -57,7 | -60,1 | -64,5 | -56,5 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -68,1 -63,0 -8.17% | -36,3 -66,0 44.97% | -70,3 -56,8 -23.59% | -8,40 -60,1 86.03% | -67,0 -64,6 -3.64% | -63,9 -59,8 -6.8% | -50,9 -63,1 19.39% | -52,9 -49,8 -6.37% | -60,7 -50,6 -19.93% | -49,1 | -50,5 | -51,8 | -50,2 | -52,6 |
Net income Million USD | Released Forecast Spread | -68,1 -72,3 5.72% | -36,3 -66,0 44.97% | -70,3 -75,6 7.09% | -8,40 -74,4 88.71% | -67,0 -71,2 6.02% | -63,9 -70,7 9.59% | -50,9 -66,6 23.66% | -52,9 -60,2 12.01% | -60,7 -50,6 -19.93% | -49,1 | -50,5 | -51,8 | -50,2 | -52,6 |
EPS USD | Released Forecast Spread | -0,28 -0,29 1.87% | -0,15 -0,28 47.13% | -0,28 -0,31 8.6% | -0,03 -0,24 87.55% | -0,27 -0,28 4.7% | -0,26 -0,27 4.88% | -0,20 -0,25 21.41% | -0,20 -0,23 12.51% | -0,24 -0,21 -13.44% | -0,20 | -0,21 | -0,21 | -0,24 | -0,21 |
Announcement Date | 10/05/22 | 04/08/22 | 08/11/22 | 28/02/23 | 04/05/23 | 08/08/23 | 07/11/23 | 28/02/24 | 06/05/24 | - | - | - | - | - |
Past sector events for Lyell Immunopharma, Inc.
2024-06-05 03:51 am | PHARMAESSENTIA CORPORATION: May 2024 Sales and Revenue Release |
2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LYEL Stock
- Calendar Lyell Immunopharma, Inc.